1 / 36

Biotransformation of Drugs

Biotransformation of Drugs. September 10, 2007 Frank F. Vincenzi. Learning objectives: drug biotransformation. Xenobiotic, endoplasmic reticulum & microsomes First pass effect, bioavailability Pro-drug, parent compound, metabolite (active or inactive) Lipophilicity vs. hydrophilicity

niyati
Download Presentation

Biotransformation of Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biotransformation of Drugs September 10, 2007 Frank F. Vincenzi

  2. Learning objectives: drug biotransformation • Xenobiotic, endoplasmic reticulum & microsomes • First pass effect, bioavailability • Pro-drug, parent compound, metabolite (active or inactive) • Lipophilicity vs. hydrophilicity • Cytochrome P-450(CYP1A2, CYP2C9 CYP2C19, CYP2D6, CYP2E1, CYP3A4* ) • Phase I vs. phase II drug metabolism • (debrisoquine) polymorphism • “Extensive” and “poor” metabolizers

  3. Really fundamental concepts in drug biotransformation • Lipid soluble drugs are poorly excreted in the urine. They tend to store in fat and/or circulate until they are converted (phase I biotransformation) to more water soluble metabolites or metabolites that conjugate (phase II biotransformation) with water soluble substances. • Water soluble drugs are more readily excreted in the urine. They may be metabolized, but generally not by the CYP enzyme systems.

  4. Drugs with major first pass effect (bioavailability) [% urinary excretion] imipramine (39) [<2] lidocaine (35) [2] morphine (24) [8] propranolol (26) [<0.5] Drugs with little or no first pass effect (bioavailability) [% urinary excretion] clonidine (95) [62] flucytosine (84) [99] metronidazole (99) [10] penicillin G (0) [>90]* (when injected) Biotransformation & urinary excretion

  5. Evolution of drug metabolizing enzymes • Terrestrial life necessitated a substantial increase in the capacity and generality of how to deal with environmental xenobiotics*, including compounds present in food.* compounds not normally present in a particular living system, ‘foreign compounds’

  6. Major biotransformation sites • Liver • Other…. • Lungs • Plasma

  7. Mixed function oxidases (monooxygenases) Cytochrome P450s or CYPs) • Add one atom of molecular oxygen to a drug substrate, another to protons to form water. • Are linked by NADPH-cytochrome P450 reductase* to the oxidation of NADPH to NADP+ • Have relatively low substrate selectivity; drugs may be metabolized by more than one CYP; the common characteristic is lipophilicity • *also called NADPH cytochrome c reductase

  8. A simple minded view of the liver endoplasmic reticulum (microsomes)

  9. Phase I biotransformation reactions* • Oxidation (mainly by mixed function oxidases) • Reduction • Hydrolysis *may result in inactivation, activation, or no change in pharmacological potency/activity

  10. Various enzymes involved in metabolism of drugs

  11. Metabolism of codeine (normal)

  12. Phase II biotransformation reactions* • Acetylation • Glucuronidation • Glutathione conjugation • Sulfation*almost always result in decreased potency and half life(notable exception morphine-6-glucuronide ~ 100 x more potent than morphine - may be created in the brain)

  13. Patient case • Donny Oregoni 12 y/o white male treated with ‘low dose’ imipramine for behavior problems and enuresis. Rx for 1 month, renewable 3x. • At three weeks Donny complains of tiredness, weakness. • At the end of a month of treatment, Donny feels poorly; Stepmother gives Donny a warm bath; he collapses and dies • Imipramine plasma level in Donny was >> 1 mg/L (therapeutic 0.1-0.3 mg/L)

  14. Genetic polymorphism ofdrug metabolizing enzymes • Donny - had abnormal CYP2D6; about 3-10% of whites, autosomal recessive • Abnormal CYP 2D6 is also known as ‘debrisoquine polymorphism’ - such patients are “slow metabolizers”, also called “poor metabolizers” of debrisoquine • Some ‘drug list’ items metabolized by 2D6: carvedilol, cevimeline, chlorpheniramine, efavirenz, imipramine, metoprolol, promethazine and timolol)

  15. Graphical representation of what happened to Donny Oregoni

  16. CYP2D6 deficiency also affects metabolism of codeine

  17. Therapeutic drug monitoring • Potentially lifesaving • Particularly important anytime dosage is changed or drugs are added or withdrawn • Expensive • For some drugs, there is no simple relationship between plasma level and therapeutic effect

  18. GeneChip®* CYP450 Assay(applied pharmacogenomics) • A matrix on a chip (high density miniaturized array of oligonucleotides) that can identify the CYP phenotype of a patient. By the year 2000 enabled rapid detection of 18 known mutations of CYP2D6 and CYP2C19. Could easily do hundreds. • In 2005 Roche AmpliChip® CYP 450 Test was approved. Cost estimated at that time was about $950 - cost will come down significantly • Something like this is likely to become a part of initial patient screening in the near future. • *http://www.affymetrix.com/

  19. Patient Case • Roberto Bolli, 22 y/o white male treated with theophylline for control of asthma. Stable on theophylline for 8 years. • Transient skin infection - prescribed 10 doses of ciprofloxacin to be taken over 5 days. • At the end of day 5, Roberto was treated in the ER for headache, nausea & vomiting and sent home. Theophylline level not determined. • Later that night, status epilepticus - theophylline level >60 mg/L (10-20 mg/L ‘therapeutic’); permanent brain damage.

  20. Inhibition of biotransformation: A basis for many different kinds of drug interaction • Ciprofloxacin (and many other compounds) inhibit CYP enzyme(s) involved in the metabolism of theophylline (CYP1A2 &/CYP3A4) • Roberto Bolli represents a tragic, but all too common, case of drug interaction. Many Rx drugs alter biotransformation. Even grapefruit juice contains an inhibitor of CYP3A4.

  21. Increased bioavailability of some drugs in patients who drink grapefruit juice

  22. Induction of drug biotransformation: Another basis of various drug interactions • polycyclic aromatic hydrocarbons, etc. - CYP1A2phenobarbital - CYP2C9 • ethanol - CYP2E1 • phenytoin - CYP3A4 • glucocorticoids, macrolide antibiotics (erythromycin, etc.), anticonvulsants - CYP3A4

  23. Some consequences of enzyme induction • Smokers metabolize theophylline faster than non-smokers - polycyclic aromatic hydrocarbons induce CYP1A1 • Chronic consumption of alcohol induces CYP2E1 - promotes ‘pharmacokinetic tolerance’ • CYP3A is inducible by macrolide antibiotics, some steroids and some anticonvulsants - may increase metabolism of a wide variety of drugs

  24. Examples of Substrates, Inhibitors and Inducers of CYPs

  25. Patient case, Heidi Raines, day 1 • Heidi Raines: 33-year-old white female, previously healthy. Two days ago developed a bad headache with nausea and vomiting. Yesterday developed a stiff neck and was told over the telephone to take Extra-Strength Excedrin according to directions on the bottle. Today made an ER visit (Dr. W) and was treated with Demerol for headache pain and, finally, was able to rest. She was felt to have a migraine and a skeletal headache and was sent home with a prescription for Demerol tablets (50 mg tabs, 1-2 q 3-4 h prn pain). Her husband was very concerned about her and wanted to do all that he could to help.

  26. Heidi Raines, day 2 • Mrs. Raines was seen (by Dr. X) in the Clinic with headache, stiff neck, nausea, and vomiting. Demerol was stopped, and she was treated with Darvon without help. Continue Extra-Strength Excedrin, 2 e 4 h prn pain.

  27. Heidi Raines, day 5 • Day 5: Mrs. Raines was seen in the Clinic (by Dr Y) and was given a prescription of Midrin®* (1 stat, then 1 q 3 h, prn). Her husband was beginning to show increased anxiety concerning her welfare. He said she had not really eaten for days because of this 'sick headache'. Once again he was reassured, and was told that he could help by taking care of her at home. He promised to be helpful. *Isometheptene, 65 mg Dichloralphenazone, 100 mg Acetaminophen, 325 mg

  28. Heidi Raines, day 6 • Day 6: Mrs Raines continued her medications and seemed to improve, although she had been unable to keep any food down for about one week. Her headache worsened and on a Clinic visit (Dr. Z) she was treated with Meprobamate and three Extra Strength Tylenol and was sent home with instructions to take three Extra Strength Tylenol every 3-4 hours, prn. Same old story with the husband.

  29. Heidi Raines, day 7 • Day 7: Continuing medications as prescribed, Mrs. Raines felt somewhat better on the day prior to admission with little headache, nausea or vomiting. However, she then developed crampy abdominal pain, anorexia, and nausea and, as per a telephone conversation, was treated with DiGel®, but, because of persistent symptoms, was admitted to the hospital.

  30. Heidi Raines, day 8 • Physical exam on admission showed a thin, 33-year-old, cigarette smoking, white female complaining of abdominal pain, nausea, vomiting, and headache. She talked in a weak voice. Her neck was supple. The chest was clear. The heart showed a sinus rhythm. There was some abdominal tenderness with no rigidity and no masses. The patient appeared pale and rather drowsy, but had no focal neurologic findings.

  31. Heidi Raines, hospital course • Liver enzymes were massively elevated with SGOT over 20,000 units. Fibrinogen level became nondetectable and platelet count continued to fall. Hematocrit and hemoglobin dropped. Bilirubin stayed stable around 3.2 mg%. Creatinine rose from 2.5 to 3.5 mgm%. The BUN was 9 or 10 mg%. Total protein was 4.5 with albumin of 3.1 grams%. Blood ammonia was 239 mg%. Neurologically, the patient deteriorated and became unresponsive. The cause of death was felt to be a respiratory arrest with subsequent cardiac arrest on the basis of severe massive hepatic necrosis (emphasis added) with metabolic changes and metabolic encephalopathy.

  32. Heidi Raines: Autopsy • 1. Acute massive necrosis of the liver • 2. Severe metabolic acidosis, lactic acidosis, treated. • 3. Acute pulm. edema, with interalveolar hemorrhage • 4. Diffuse intravascular coagulation. • 5. Acute renal failure secondary to acute tubular necrosis. • 6. Metabolic encephalopathy, secondary to hepatic coma • 7. Metabol. acidosis severe lactic acidosis, H20 depletion • 8. Anemia, ? hemolytic, ? due to blood loss into lungs.

  33. Why did Heidi Raines die? • Failure to properly diagnose and treat

  34. The husband did it!! • N-acetyl-phenylquinone imine (NAPQI) is a MINOR, but potentially toxic, metabolite of acetaminophen. NAPQI reacts with glutathione unless there is no glutathione, then NAPQI reacts with thiol groups on liver cell membranes - Voila! Liver cell death. • Normally, glutathione is rapidly synthesized in the liver from various foodstuffs. However, in animals (and people) deprived of food for a few days, synthesis of glutathione will not occur (and the toxicity of acetaminophen decreases by more than ten-fold!).

  35. Mechanism of Heidi Raines’ death

  36. Learning objectives: drug biotransformation • Xenobiotic, endoplasmic reticulum & microsomes • First pass effect, bioavailability • Pro-drug, parent compound, metabolite (active or inactive) • Lipophilicity vs. hydrophilicity • Cytochrome P-450(CYP1A2, CYP2C9 CYP2C19, CYP2D6, CYP2E1, CYP3A4* ) • Phase I vs. phase II drug metabolism • (debrisoquine) polymorphism • “Extensive” and “poor” metabolizers

More Related